The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Open accessAbstract
BACKGROUND: Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D. METHODS: We conducted a historical cohort study to compare the 36-month survival rate among patients undergoing long-term hemodialysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001. Crude and adjusted survival rates were calculated and stratified analyses were performed. A subgroup of 16,483 patients who switched regimens was also evaluated. RESULTS: The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per person-year), as compared with 6805 per 30,471 person-years (0.223 per person-year) among those receiving calcitriol (P<0.001). The difference in survival was significant at 12 months and increased with time (P<0.001). In the adjusted analysis, the mortality rate was 16 percent lower (95 percent confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-treated patients. A significant survival benefit was evident in 28 of 42 strata examined, and in no stratum was calcitriol favored. At 12 months, calcium and phosphorus levels had increased by 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001). The two-year survival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent among those who switched from paricalcitol to calcitriol (P=0.04). CONCLUSIONS: Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol. A prospective, randomized study is critical to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Goodman, W. G., Goldin, J., Kuizon, B. D., Yoon, C., Gales, B., Sider, D., Wang, Y., Chung, J., Emerick, A., Greaser, L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422003 · Cited by 2,509
Block, G., Hulbert-Shearon, T., Levin, N., & Port, F. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,354
Oodman, W. I. G. G., Oldin, J. O. G., Uizon, D. K., Oon, C. H. Y., Ales, B. A. G., Ider, D. O. S., Ang, W. C., Oanie, J., Hung, C., Merick, A. L. E., et al. (2000) · Cited by 2,191
Lowrie, E. G., & Lew, N. L. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70364-5 · Cited by 1,976
Self-citationSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462
Owen, W. F., Lew, N. L., Liu, Y., Lowrie, E. G., & Lazarus, J. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291404 · Cited by 1,404
Self-citationGANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Oh, J., Wunsch, R., Turzer, M., Bahner, M., Raggi, P., Querfeld, U., Mehls, O., & Schaefer, F. (2002) · Circulation · doi:10.1161/01.cir.0000020222.63035.c0 · Cited by 722
Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone
Coco, M., & Rush, H. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19812 · Cited by 603
Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins
Moe, S. M., O'Neill, K. D., Duan, D., Ahmed, S., Chen, N. X., Leapman, S. B., Fineberg, N., & Kopecky, K. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00170.x · Cited by 448
Risk factors for vertebral fractures in renal osteodystrophy
Atsumi, K., Kushida, K., Yamazaki, K., Shimizu, S., Ohmura, A., & Inoue, T. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70302-1 · Cited by 321
Goodman, W. G., Ramirez, J. A., Belin, T. R., Chon, Y., Gales, B., Segre, G. V., & Salusky, I. B. (1994) · Kidney International · doi:10.1038/ki.1994.380 · Cited by 318
Pathophysiological mechanisms of vascular calcification in end-stage renal disease
Davies, M. R., & Hruska, K. A. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060002472.x · Cited by 259
Peleg, S., Sastry, M., Collins, E. D., Bishop, J. E., & Norman, A. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10551 · Cited by 200
Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon
Qunibi, W. Y., Nolan, C. A., & Ayus, J. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.62.s82.15.x · Cited by 141
Assaf, A. R., Lapane, K. L., McKenney, J. L., & Carleton, R. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309233291307 · Cited by 123
Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
Gupta, A., Kallenbach, L., Zasuwa, G., & Divine, G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v112330 · Cited by 120
1 -Hydroxyvitamin D2 is Less Toxic than 1 -Hydroxyvitamin D3 in the Rat
Sjoden, G., Smith, C. M., Lindgren, U., & Deluca, H. F. (1985) · Experimental Biology and Medicine · doi:10.3181/00379727-178-42028 · Cited by 116
Impact of hematocrit on morbidity and mortality.
Collins, A. J., Z, J., & Ebben, J. (2000) · PubMed · Cited by 108
Therapeutic uses of vitamin D analogues
Brown, A. J. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.28111 · Cited by 87
Care of Patients Undergoing Hemodialysis
Ifudu, O. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391507 · Cited by 82
ARTERIAL CALCIFICATION AFTER VITAMIN-D THERAPY IN HYPERPHOSPHATÆMIC RENAL FAILURE
Mallick, N. P., & Berlyne, G. M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)91816-3 · Cited by 74
Calcemic Activity of 19-Nor-1,25(OH)2D2 Decreases with Duration of Treatment
Brown, A. J., Finch, J. L., Takahashi, F., & Slatopolsky, E. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11112088 · Cited by 48
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citationVitamin D signalling pathways in cancer: potential for anticancer therapeutics
Deeb, K. K., Trump, D. L., & Johnson, C. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2196 · Cited by 1,419
Dobnig, H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.12.1340 · Cited by 1,209
Isakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,020
Metadata
- Authors
- Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-31
- Volume
- 349
- Issue
- 5
- Pages
- 446-456
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105417592
- Cited by
- 927
- References
- 25
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.